Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

NCT02782624 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Empagliflozin
DRUG: Empagliflozin

Sponsor

Boehringer Ingelheim